10 rezilta yo
This application claims the benefit of Korean Patent Application No 10-2016-0099978, filed Aug. 5, 2016, the entirety of which is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for preventing or treating liver cancer containing
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 35 U.S.C. .sctn. 371 National Phase Entry Application from PCT/KR2013/007852, filed on Aug. 30, 2013, and designating the United States, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The present invention
FIELD OF INVENTION
This invention relates to a novel ginsenoside compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.
BACKGROUND OF INVENTION
In the past decades, a number of anti-cancer drugs have been discovered from natural products, which
FIELD OF THE INVENTION
The invention is in the field of therapeutic compositions and methods, particularly chemotherapy of cancer using ginsenosides.
BACKGROUND OF THE INVENTION
Panax ginseng has served as an important component of traditional Chinese medicine for thousands of years. Recently,
This application claims priority upon Korean. Patent application Ser. No. KR 10-2005-00305 19 filed on Apr. 12, 2005, the contents of which are all herein incorporated by this reference in their entireties. All publications, patents, patent applications, databases and other references cited in this
TECHNICAL FIELD
The invention belongs to the field of medicines, and relates to a medicine or health food for treating human cytomegalovirus infection, particularly to application of ginseng (a traditional Chinese medicine) extracts and derivatives thereof in medicines or health foods for treating
TECHNOLOGICAL FIELD OF THE INVENTION
This invention relates to a ginsenoside Rg3 pharmaceutical composition and process thereof.
TECHNOLOGICAL BACKGROUND OF THE INVENTION
Ginsenoside Rg3 is a tetracyclic-triterpene saponin compound existed in Ginseng, with a molecular weight of 784.13. There are two
TECHNOLOGICAL FIELD OF THE INVENTION
This invention relates to a ginsenoside Rg3 pharmaceutical composition and process thereof.
TECHNOLOGICAL BACKGROUND OF THE INVENTION
Ginsenoside Rg3 is a tetracyclic-triterpene saponin compound existed in Ginseng, with a molecular weight of 784.13. There are two
This application is the U.S. National phase application corresponding to PCT/CN2014/094726 which was assigned an international filing date of Dec. 23, 2014 and associated with publication WO 2016/095249 A1 and which claims priority to Chinese Application 2014107851724 filed on Dec. 17, 2014, the
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Stage Application filed under 35 U.S.C. .sctn. 371 and claims priority to International Application No. PCT/KR2015/006832, filed Jul. 2, 2015, which application claims priority to Korean Application No. 10-2015-0071477,